Janssen

Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Clinical Trials Arena
JNJ
Janssen
Tremfya
psoriasis
real world data
Flag link:
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
Clinical Trials Arena
JNJ
Janssen
clinical trials
Tremyfa
ulcerative colitis
Flag link:
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
BioSpace
JNJ
Janssen
Cellular Biomedicine
CAR-T
diffuse large B-cell lymphoma
Flag link:
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways
Benzinga
Genmab
JNJ
Janssen
Darzalex
Flag link:
J&J claims first approval for PARP combo Akeega
J&J claims first approval for PARP combo Akeega
Pharmaphorum
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
Flag link:
J&J records $130M restructuring expense in Q1 overhaul of infectious disease unit
J&J records $130M restructuring expense in Q1 overhaul of infectious disease unit
Fierce Biotech
JNJ
Janssen
earnings
restructuring
infectious disease
Flag link:
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Fierce Pharma
JNJ
patents
Janssen
Amgen
biosimilars
Stelara
Flag link:
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
Fierce Biotech
JNJ
Janssen
nipocalimab
Momenta Pharmaceuticals
Flag link:
Janssen Returns Phase I NASH Candidate to Arrowhead
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Flag link:
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
BioSpace
Roche
Janssen
JNJ
companion diagnostics
diagnostics
Flag link:
J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout
J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout
Endpoints
JNJ
Momenta
Janssen
nipocalimab
clinical trials
Flag link:
Janssen laying off 4 dozen employees as California plant heads toward closure
Janssen laying off 4 dozen employees as California plant heads toward closure
Fierce Pharma
JNJ
Janssen
layoffs
California
drug manufacturing
Doxil
Concerta
Flag link:
Morphic Loses Another Big Pharma as J&J Bails on Research Deal
Morphic Loses Another Big Pharma as J&J Bails on Research Deal
BioSpace
JNJ
Janssen
Morphic Therapeutic
R&D
Flag link:
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
antibody-drug conjugate
Merck
LegoChem Biosciences
Mersana
Amgen
GSK
Janssen
Flag link:
Setting the Stage for ASH 2022
Setting the Stage for ASH 2022
BioSpace
ASH 2022
AstraZeneca
Janssen
Merck
Vega Therapeutics
Flag link:
Janssen Bows Out as Contender for Horizon Therapeutics Buyout
Janssen Bows Out as Contender for Horizon Therapeutics Buyout
BioSpace
Horizon Therapeutics
M&A
Agmen
Sanofi
Janssen
JNJ
Flag link:
J&J sues Amgen over plan to sell drug similar to Stelara
J&J sues Amgen over plan to sell drug similar to Stelara
Business Insurance
JNJ
Janssen
Amgen
legal
ulcerative colitis
patents
Stelara
Flag link:
J&J unit, happy with AC Immune Alzheimer's work, moves 1 of 2 shots to next step
J&J unit, happy with AC Immune Alzheimer's work, moves 1 of 2 shots to next step
Fierce Biotech
JNJ
AC Immune
Alzheimer's disease
Janssen
vaccines
ACI-35.030
Flag link:
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
Clinical Trials Arena
Janssen
JNJ
clinical trials
Spravato
treatment-resistant depression
Flag link:
Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollment Issues
Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollment Issues
BioSpace
Essa Pharma
Janssen
JNJ
prostate cancer
clinical trials
EPI-7386
Flag link:

Pages